United States Leads the Radiopharmaceuticals Market as Theranostics, Oncology Imaging & Lu-177 Therapies Drive 10.8% CAGR to US$19.69 Billion by 2033

The radiopharmaceuticals market size reached US$ 7.91 billion in 2024 from US$ 7.20 billion in 2023 and is expected to reach US$ 19.69 billion by 2033, growing at a CAGR of 10.8% from 2025 to 2033. This robust growth is driven by the increasing prevalence of cancer and cardiovascular diseases necessitating advanced diagnostic imaging and targeted therapies, rapid adoption of theranostics combining diagnostics and treatment, advancements in cyclotron and reactor production for isotopes like F-18 and Lu-177, expanding approvals for novel agents in oncology and neurology, and growing investments in personalized nuclear medicine.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/radiopharmaceuticals-market?sindhuri

North America: Key Industry Developments (Largest Region)
✅ November 2025: Novartis expanded U.S. production capacity for Pluvicto (Lu-177 vipivotide tetraxetan) to meet surging demand in prostate cancer therapy.
✅ October 2025: Eli Lilly received FDA approval for new diagnostic agents complementing its oncology radiopharmaceutical pipeline.
✅ September 2025: Cardinal Health enhanced distribution networks for ready-to-use radiotracers, supporting hospital-based nuclear medicine programs.

Asia Pacific: Key Industry Developments (Fastest Growing Region)
✅ November 2025: Regional investments in cyclotron facilities accelerated in China and India to reduce import dependency for FDG and other tracers.
✅ October 2025: Government initiatives promoted local production of Ga-68 and Lu-177 agents for cancer diagnostics and therapy.
✅ September 2025: Partnerships expanded clinical trials and approvals for theranostic agents in high-prevalence oncology markets.

Key Mergers and Acquisitions :
✅ Bristol Myers Squibb strengthens portfolio: Ongoing integrations from prior acquisitions enhanced rayzebio-derived targeted radiotherapy candidates.
✅ Novartis and Lilly expansions: Strategic investments and partnerships bolstered production and pipeline for prostate and neuroendocrine tumor treatments.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=radiopharmaceuticals-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis:
-By Type: Diagnostic Radiopharmaceuticals Lead with Dominant Share
The Diagnostic Radiopharmaceuticals segment commands the largest market share, driven by widespread use of PET and SPECT imaging with agents like FDG for oncology and cardiology.
Therapeutic Radiopharmaceuticals are the fastest-growing, fueled by targeted alpha and beta emitters like Lu-177 and Ac-225.
-By Application: Oncology Commands Largest Portion
Oncology dominates due to high cancer incidence and precision targeting needs.
Cardiology and Neurology see strong growth with specialized tracers.
-By Radioisotope: Technetium-99m and Fluorine-18 Top with Strong Demand
Technetium-99m leads for SPECT diagnostics; emerging Lutetium-177 drives therapeutic expansion.

Growth Drivers:
Rising Cancer and Cardiovascular Prevalence - Increasing need for precise diagnostics and targeted therapies.
Theranostics Boom - Combining diagnosis and treatment with paired agents like Ga-68/Lu-177.
Technological Advancements - Improved production, longer half-life isotopes, and alpha emitters.
Regulatory Approvals and Reimbursements - Supporting novel agents in prostate, neuroendocrine, and other cancers.
Investments in Nuclear Medicine Infrastructure - Expanding cyclotrons and radiopharmacies globally.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/radiopharmaceuticals-market?sindhuri

Regional Insights:
North America dominates the global Radiopharmaceuticals market, accounting for the largest share due to advanced nuclear medicine facilities, high adoption of PET/CT, strong reimbursement, rapid FDA approvals, and presence of leading innovators.
Asia-Pacific is the fastest-growing region, driven by rising cancer burden, investments in local production, improving healthcare infrastructure, and government support in populous nations.

Key Players:
Novartis AG | Eli Lilly and Company | Bayer AG | Siemens Healthineers | GE Healthcare | Cardinal Health | Curium Pharma | Lantheus Holdings, Inc. | Bracco Imaging S.p.A. | Jubilant Pharmova Limited

Key Highlights (Top 5 Key Players) for Radiopharmaceuticals Market:
1. Novartis AG leads with blockbuster theranostics like Pluvicto and Lutathera, expanding production for prostate and neuroendocrine tumors.
2. Eli Lilly and Company strengthens through acquisitions and approvals in diagnostic/therapeutic pairs.
3. Bayer AG innovates in precision oncology with targeted radioligand therapies.
4. Siemens Healthineers excels in imaging systems and tracers for enhanced diagnostics.
5. GE Healthcare differentiates with reliable supply of FDG and specialized generators.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.